AR and prostate cancer: In light of these findings, Squillace et al. (82) recently demonstrated that dual inhibition of AR and mTOR with bicalutamide and ridaforolimus, respectively, had synergistic antiproliferative effect in prostate cancer cells in vitro when compared with each agent alone (82).